Can Parkinson's disease pathology be propagated from one neuron to another?

Progress in Neurobiology

Volumn 97, Issue 2, 2012, Pages 205-219

  Dunning, Christopher J R ^a   Reyes, Juan F ^a   Steiner, Jennifer A ^a   Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Synuclein; Cell to cell transfer; Neurodegenerative disease; Parkinson's disease; Prion like

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; HEAT SHOCK PROTEIN 70; HUNTINGTIN; LEUCINE RICH REPEAT KINASE 2; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPHAGY; BRAIN REGION; CALCIUM CELL LEVEL; CELL TRANSPORT; CEREBROSPINAL FLUID; CONCENTRATION (PARAMETERS); CONSTIPATION; DISEASE COURSE; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; EXOCYTOSIS; EXOSOME; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; IMMUNOREACTIVITY; INTERNALIZATION; LEWY BODY; LOCUS CERULEUS; NEOCORTEX; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN TRANSPORT; RAPHE NUCLEUS; REVIEW; SMELLING DISORDER; SUBSTANTIA NIGRA PARS COMPACTA; VIRUS INFECTION;

ALPHA-SYNUCLEIN; ANIMALS; CELL COMMUNICATION; HUMANS; NEURONS; PARKINSON DISEASE; PROTEIN TRANSPORT;

EID: 84860686110     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.11.003     Document Type: Review

References (210)

1. Abbott R.D., Petrovitch H., White L.R., Masaki K.H., Tanner C.M., Curb J.D., Grandinetti A., Blanchette P.L., Popper J.S., Ross G.W. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001, 57:456-462.
2. Aguzzi A., Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009, 64:783-790.
3. Ahn K.J., Paik S.R., Chung K.C., Kim J. Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J. Neurochem. 2006, 97:265-279.
4. Allen B., Ingram E., Takao M., Smith M.J., JAKES R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2002, 22:9340-9351.
5. Alvarez-Erviti L., Seow Y., Schapira A.H., Gardiner C., Sargent I.L., Wood M.J.A., Cooper J.M. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol. Dis. 2011, 42:360-367.
6. Amijee H., Madine J., Middleton D.A., Doig A.J. Inhibitors of protein aggregation and toxicity. Biochem. Soc. Trans. 2009, 37:692-696.
7. Angot E.A., Steiner J.A.S., Hansen C.H., Li J.-Y., Brundin P.B. Are synucleinopathies prion-like disorders?. Lancet Neurol. 2010, 9:1128-1138.
8. Angot, E.A., Steiner, J.A., Lema Tomé, C.M., Mattsson, B., Björklund, A., Brundin, P., 2011. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo, submitted.
9. Angot E., Brundin P. Dissecting the potential molecular mechanisms underlying α-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:S143-S147.
10. Attems J., Jellinger K.A. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. Neuropathol. Appl. Neurobiol. 2008, 34:466-467.
11. Auluck P.K., Caraveo G., Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 2010, 26:211-233.
12. Bartels T., Choi J.G., Selkoe D.J. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477(7362):107-110.
13. Berry C., La Vecchia C., Nicotera P. Paraquat and Parkinson's disease. Cell Death Differ. 2010, 17:1115-1125.
14. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
15. Borchelt D.R., Lee M.K., Slunt H.S., Guarnieri M., Xu Z.S., Wong P.C., Brown R.H., Price D.L., Sisodia S.S., Cleveland D.W. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8292-8296.
16. Braak H., de Vos R.A.I., Bohl J., Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 2006, 396:67-72.
17. Braak H., Ghebremedhin E., R b U., Bratzke H.R., Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
18. Braak H., Del Tredici K. Invited Article: nervous system pathology in sporadic Parkinson disease. Neurology 2008, 70:1916-1925.
19. Braak H., Del Tredici K., Rüb U., de Vos R.A.I., Jansen Steur E.N.H., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
20. Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 2002, 249(Suppl 3). III/1-5.
21. Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. Eur. Neurol. 1993, 33:403-408.
22. Brown T.P., Rumsby P.C., Capleton A.C., Rushton L., Levy L.S. Pesticides and Parkinson's disease-is there a link?. Environ. Health Perspect. 2006, 114:156-164.
23. Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004, 27:723-749.
24. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
25. Brundin P., Olsson R. Can α-synuclein be targeted in novel therapies for Parkinson's disease?. Exp. Rev. Neurother. 2011, 11:917-919.
26. Brundin P., Melki R., Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 2010, 11:301-307.
27. Brundin P., Li J.-Y., Holton J.L., Lindvall O., Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Med. 2008, 9:741-745.
28. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Südhof T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
29. Chandra S., Fornai F., Kwon H.-B., Yazdani U., Atasoy D., Liu X., Hammer R.E., Battaglia G., German D.C., Castillo P.E., et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14966-14971.
30. Chartier-Harlin M.-C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
31. Chattopadhyay M., Valentine J.S. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid. Redox Signal. 2009, 11:1603-1614.
32. Chen C.C., Chen T.F., Hwang Y.C., Wen Y.R., Chiu Y.H., Wu C.Y., Chen R.C., Tai J.J., Chen T.H.H., Liou H.H. Different prevalence rates of Parkinson's disease in urban and rural areas: a population-based study in Taiwan. Neuroepidemiology 2009, 33:350-357.
33. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
34. Choi D.-H., Kim Y.-J., Kim Y.-G., Joh T.H., Beal M.F., Kim Y.-S. Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. J. Biol. Chem. 2011, 286:14168-14177.
35. Chu Y., Kordower J.H. Lewy body pathology in fetal grafts. Ann. N. Y. Acad. Sci. 2010, 1184:55-67.
36. Chu Y., Kordower J.H. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?. Neurobiol. Dis. 2007, 25:134-149.
37. Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
38. Colby D.W., Prusiner S.B. Prions. Cold Spring Harb. Perspect. Biol. 2011, 3(1). a006833.
39. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Med. 2011, 12:359-366.
40. Cookson M.R., Bandmann O. Parkinson's disease: insights from pathways. Hum. Mol. Gen. 2010, 19:R21-R27.
41. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
42. Crouch P.J., Harding S-M.E., White A.R., Camakaris J., Bush A.I., Masters C.L. Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int. J. Biochem. Cell Biol. 2008, 40:181-198.
43. Daniel S.E., Hawkes C.H. Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. Lancet 1992, 340:186.
44. Danzer K.M., Ruf W.P., Putcha P., Joyner D., Hashimoto T., Glabe C., Hyman B.T., McLean P.J. Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 2011, 25:326-336.
45. Danzer K.M., Krebs S.K., Wolff M., Birk G., Hengerer B. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J. Neurochem. 2009, 111:192-203.
46. Danzer K.M., Haasen D., Karow A.R., Moussaud S., Habeck M., Giese A., Kretzschmar H., Hengerer B., Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 2007, 27:9220-9232.
47. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979, 1:249-254.
48. De Maio A. Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: a form of communication during injury, infection, and cell damage. Cell Stress Chaperones 2011, 16:235-249.
49. Dehay B., Bové J., Rodríguez-Muela N., Perier C., Recasens A., Boya P., Vila M. Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 2010, 30:12535-12544.
50. Desplats P., Lee H.-J., Bae E.-J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.-J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13010-13015.
51. Doty R.L., Shaman P., Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol. Behav. 1984, 32:489-502.
52. Duda J.E., Lee V.M., Trojanowski J.Q. Neuropathology of synuclein aggregates. J. Neurosci. Res. 2000, 61:121-127.
53. Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., Wang L., Zuchner S., Konidari I., Wang G., et al. Genome-Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease. Ann. Hum. Genet. 2010, 74:97-109.
54. Eisele Y.S., Obermuller U., Heilbronner G., Baumann F., Kaeser S.A., Wolburg H., Walker L.C., Staufenbiel M., Heikenwalder M., Jucker M. Peripherally applied abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010, 330:980-982.
55. El-Agnaf O.M.A., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M.A., Ikeda S.-I., et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003, 17:1945-1947.
56. Emmanouilidou E., Melachroinou K., Roumeliotis T., Garbis S.D., Ntzouni M., Margaritis L.H., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 2010, 30:6838-6851.
57. Emmanouilidou E., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 2010, 31:953-968.
58. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., West A., de Silva R., Hardy J., Hernandez D. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Gen. 2001, 10:1847-1851.
59. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., Forno L., Gwinn-Hardy K., Petrucelli L., Hussey J., et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 2001, 50:293-300.
60. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
61. Fevrier B., Vilette D., Archer F., Loew D., Faigle W., Vidal M., Laude H., Raposo G. Cells release prions in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9683-9688.
62. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
63. Frost B., Jacks R.L., Diamond M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284:12845-12852.
64. Fuchs J., Tichopad A., Golub Y., Munz M., Schweitzer K.J., Wolf B., Berg D., Mueller J.C., Gasser T. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008, 22:1327-1334.
65. Gagnon J.F., Postuma R.B., Mazza S., Doyon J., Montplaisir J. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006, 5:424-432.
66. Gagnon J.F., Bédard M.A., Fantini M.L., Petit D., Panisset M., Rompré S., Carrier J., Montplaisir J. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002, 59:585-589.
67. Gerdes H.-H., Carvalho R.N. Intercellular transfer mediated by tunneling nanotubes. Curr. Opin. Cell Biol. 2008, 20:470-475.
68. Gerdes H.-H., Bukoreshtliev N.V., Barroso J.F.V. Tunneling nanotubes: a new route for the exchange of components between animal cells. FEBS Lett. 2007, 581:2194-2201.
69. Gousset K., Schiff E., Langevin C., Marijanovic Z., Caputo A., Browman D.T., Chenouard N., de Chaumont F., Martino A., Enninga J., et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 2009, 11:328-336.
70. Halliday G.M., McCann H. The progression of pathology in Parkinson's disease. Ann. N. Y. Acad. Sci. 2010, 1184:188-195.
71. Hansen C., Angot E., Bergström A.-L., Steiner J.A., Pieri L., Paul G., Outeiro T.F., Melki R., Kallunki P., Fog K., et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121:715-725.
72. Hawkes C.H., Del Tredici K., Braak H. A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 2010, 16:79-84.
73. Hawkes C.H., Del Tredici K., Braak H. Parkinson's disease: the dual hit theory revisited. Ann. N. Y. Acad. Sci. 2009, 1170:615-622.
74. Hawkes C.H., Del Tredici K., Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 2007, 33:599-614.
75. Hoffner G., Djian P. Protein aggregation in Huntington's disease. Biochimie 2002, 84:273-278.
76. Hummel T., Sekinger B., Wolf S.R., Pauli E., Kobal G. Sniffin 'sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem. Senses 1997, 22:39-52.
77. International Parkinson Disease Genomics Consortium Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
78. Iranzo A., Molinuevo J.L., Santamaría J., Serradell M., Martí M.J., Valldeoriola F., Tolosa E. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006, 5:572-577.
79. Jang A., Lee H.-J., Suk J.-E., Jung J.-W., Kim K.-P., Lee S.-J. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 2010, 113:1263-1274.
80. Jang H., Boltz D., Sturm-Ramirez K., Shepherd K.R., Jiao Y., Webster R., Smeyne R.J. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14063-14068.
81. Jang H., Boltz D.A., Webster R.G., Smeyne R.J. Viral parkinsonism. BBA-Mol. Basis Dis. 2009, 1792:714-721.
82. Jayasinghe S.A., Langen R. Membrane interaction of islet amyloid polypeptide. Biochim. Biophys. Acta 2007, 1768:2002-2009.
83. Jellinger K.A. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim. Biophys. Acta 2009, 1792:730-740.
84. Jellinger K.A. Absence of α-synuclein pathology in postencephalitic parkinsonism. Acta Neuropathol. 2009, 118:371-379.
85. Jellinger K.A. Formation and development of Lewy pathology: a critical update. J. Neurol. 2009, 256(Suppl. 3):270-279.
86. Jellinger K.A. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 2008, 116:1-16.
87. Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.-P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40:572-574.
88. Kalaitzakis M.E., Graeber M.B., Gentleman S.M., Pearce R.K.B. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol. Appl. Neurobiol. 2008, 34:284-295.
89. Klegeris A., Pelech S., Giasson B.I., Maguire J., Zhang H., McGeer E.G., McGeer P.L. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 2008, 29:739-752.
90. Klegeris A., Giasson B.I., Zhang H., Maguire J., Pelech S., McGeer P.L. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J. 2006, 20:2000-2008.
91. Kondo K., Obitsu S., Teshima R. α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol. Pharm. Bull. 2011, 34:1078-1083.
92. Kordower J.H., Dodiya H.B., Kordower A.M., Terpstra B., Paumier K., Madhavan L., Sortwell C., Steece-Collier K., Collier T.J. Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol. Dis. 2011.
93. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
94. Kordower J.H., Chu Y., Hauser R.A., Olanow C.W., Freeman T.B. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov. Disord. 2008, 23:2303-2306.
95. Krammer C., Schätzl H.M., Vorberg I. Prion-like propagation of cytosolic protein aggregates: insights from cell culture models. Prion 2009, 3:206-212.
96. Krueger M.J., Singer T.P., Casida J.E., Ramsay R.R. Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone. Biochem. Biophys. Res. Commun. 1990, 169:123-128.
97. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
98. Kurowska Z., Englund E., Widnerd H., Lindvalle O., Lia J.-Y., Brundin P. Signs of Degeneration in 12-22-Year Old Grafts of Mesencephalic Dopamine Neurons in Patients with Parkinson's Disease. J. Park. Dis. 2011, 83-92.
99. Lancaster G.I., Febbraio M.A. Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J. Biol. Chem. 2005, 280:23349-23355.
100. Langston J.W. The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann. Neurol. 2006, 59:591-596.
101. Langston J.W., Ballard P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 1983, 309:310.
102. Lässer C., Alikhani V.S., Ekström K., Eldh M., Paredes P.T., Bossios A., Sjöstrand M., Gabrielsson S., Lötvall J., Valadi H. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J. Transl. Med. 2011, 9:9.
103. Lebouvier T., Chaumette T., Paillusson S., Duyckaerts C., Bruley des Varannes S., Neunlist M., Derkinderen P. The second brain and Parkinson's disease. Eur. J. Neurosci. 2009, 30:735-741.
104. Lebouvier T., Neunlist M., Bruley des Varannes S., Coron E., Drouard A., N'Guyen J.-M., Chaumette T., Tasselli M., Paillusson S., Flamand M., et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS ONE 2010, 5:e12728.
105. Lee B.D., Shin J.-H., VanKampen J., Petrucelli L., West A.B., Ko H.S., Lee Y.-I., Maguire-Zeiss K.A., Bowers W.J., Federoff H.J., et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med. 2010, 16:998-1000.
106. Lee E.-J., Woo M.-S., Moon P.-G., Baek M.-C., Choi I.-Y., Kim W.-K., Junn E., Kim H.-S. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J. Immunol. 2010, 185:615-623.
107. Lee H.J., Suk J.-E., Bae E.-J., Lee J.-H., Paik S.R., Lee S.-J. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int. J. Biochem. Cell Biol. 2008, 40:1835-1849.
108. Lee S.-J. Origins and Effects of Extracellular α-synuclein: implications in Parkinson's Disease. J. Mol. Neurosci. 2007, 34(1):17-22.
109. Lee H.-J., Patel S., Lee S.-J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 2005, 25:6016-6024.
110. Lee K.-W., Chen W., Junn E., Im J.-Y., Grosso H., Sonsalla P.K., Feng X., Ray N., Fernandez J.R., Chao Y., et al. Enhanced phosphatase activity attenuates α-Synucleinopathy in a mouse model. J. Neurosci. 2011, 31:6963-6971.
111. Lee S.-J., Lim H.-S., Masliah E., Lee H.-J. Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives. Neurosci. Res. 2011.
112. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
113. Li J.-Y., Englund E., Widner H., Rehncrona S., Björklund A., Lindvall O., Brundin P. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 2010, 25:1091-1096.
114. Li J.-Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Björklund A., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
115. Li W., Lesuisse C., Xu Y., Troncoso J.C., Price D.L., Lee M.K. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J. Neurosci. 2004, 24:7400-7409.
116. Lincoln S., Crook R., Chartier-Harlin M.C., Gwinn-Hardy K., Baker M., Mouroux V., Richard F., Becquet E., Amouyel P., Destée A., et al. No pathogenic mutations in the beta-synuclein gene in Parkinson's disease. Neurosci. Lett. 1999, 269:107-109.
117. Lotharius J., Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Gen. 2002, 11:2395-2407.
118. Lotharius J., O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 2000, 275:38581-38588.
119. Luk K.C., Song C., O'Brien P., Stieber A., Branch J.R., Brunden K.R., Trojanowski J.Q., Lee V.M-Y. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. U. S. A 2009, 106:20051-20056.
120. Luk K.C., Song C., O'Brien P., Stieber A., Branch J.R., Brunden K.R., Trojanowski J.Q., Lee V.M.-Y. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. U. S. A 2009, 106:20051-20056.
121. Mata I.F., Shi M., Agarwal P., Chung K.A., Edwards K.L., Factor S.A., Galasko D.R., Ginghina C., Griffith A., Higgins D.S., et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch. Neurol. 2010, 67:1350-1356.
122. Mercer J., Helenius A. Virus entry by macropinocytosis. Nat. Cell Biol. 2009, 11:510-520.
123. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., Kaeser S., Schaefer C., Kilger E., Neuenschwander A., Abramowski D., Frey P., Jaton A.L., et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
124. Morales R., Duran-Aniotz C., Castilla J., Estrada L.D., Soto C. De novo induction of amyloid-β deposition in vivo. Mol. Psychiatry 2011.
125. Moss J., Bolam J.P. The relationship between dopaminergic axons and glutamatergic synapses in the striatum: structural considerations. Dopamine Handbook 2010, 49-59. Oxford University Press, Oxford, UK. L.L. Iversen, S.D. Iversen, S.B. Dunnett, A. Björklund (Eds.).
126. Mougenot A.-L., Nicot S., Bencsik A., Morignat E., Verchère J., Lakhdar L., Legastelois S., Baron T. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 2011.
127. Muhammad A., Flores I., Zhang H., Yu R., Staniszewski A., Planel E., Herman M., Ho L., Kreber R., Honig L.S., et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7327-7332.
128. Müller A., Reichmann H., Livermore A., Hummel T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J. Neural. Transm. 2002, 109:805-811.
129. Münch C., O'Brien J., Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3548-3553.
130. Neumann M., Kahle P.J., Giasson B.I., Ozmen L., Borroni E., Spooren W., Müller V., Odoy S., Fujiwara H., Hasegawa M., et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 2002, 110:1429-1439.
131. Nonaka T., Watanabe S.T., Iwatsubo T., Hasegawa M. Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem. 2010, 285:34885-34898.
132. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., Hirsch E.C., Farrer M., Schapira A.H.V., Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 2010, 16:653-661.
133. Ohtake H., Limprasert P., Fan Y., Onodera O., Kakita A., Takahashi H., Bonner L.T., Tsuang D.W., Murray I.V.J., Lee V.M.Y., et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004, 63:805-811.
134. Okabayashi S., Kimura N. LGI3 interacts with flotillin-1 to mediate APP trafficking and exosome formation. Neuro Report 2010, 21:606-610.
135. Olanow C.W., Perl D.P., DeMartino G.N., McNaught K.S.P. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 2004, 3:496-503.
136. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Bonucelli U., Damier P., De Yebenes J., Gershanik O., Guttman M., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 2004, 19:997-1005.
137. Onfelt B., Purbhoo M.A., Nedvetzki S., Sowinski S., Davis D.M. Long-distance calls between cells connected by tunneling nanotubules. Sci. STKE 2005 2005, pe55.
138. Oueslati A., Fournier M., Lashuel H.A. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 2010, 183:115-145.
139. Pals P., Lincoln S., Manning J., Heckman M., Skipper L., Hulihan M., Van den Broeck M., De Pooter T., Cras P., Crook J., et al. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 2004, 56:591-595.
140. Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 2002, 14(2). Spring.
141. Parkkinen L., Pirttilä T., Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008, 115:399-407.
142. Pearce R.K., Hawkes C.H., Daniel S.E. The anterior olfactory nucleus in Parkinson's disease. Mov. Disord. 1995, 10:283-287.
143. Petrovitch H., Abbott R.D., Ross G.W., Nelson J., Masaki K.H., Tanner C.M., Launer L.J., White L.R. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov. Disord. 2009, 24:371-376.
144. Poewe W., Antonini A., Zijlmans J.C., Burkhard P.R., Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin. Interv. Aging 2010, 5:229-238.
145. Poewe W. The natural history of Parkinson's disease. J. Neurol. 2006, 253(Suppl. 7). VII2-6.
146. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
147. Ponsen M.M., Stoffers D., Booij J., van Eck-Smit B.L.F., Wolters E.C., Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 2004, 56:173-181.
148. Prudencio M., Hart P.J., Borchelt D.R., Andersen P.M. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum. Mol. Genet. 2009, 18:3217-3226.
149. Prusiner S. Prion Biology and Diseases 2004, Cold Spring Harbor Lab Press, Cold Spring Harbor, NY. 2nd ed.
150. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216:136-144.
151. Rajendran L., Honsho M., Zahn T.R., Keller P., Geiger K.D., Verkade P., Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11172-11177.
152. Rascol O., Lozano A., Stern M., Poewe W. Milestones in Parkinson's disease therapeutics. Mov. Disord. 2011, 26:1072-1082.
153. Record M., Subra C., Silvente-Poirot S., Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 2011, 81:1171-1182.
154. Reichmann H. Clinical criteria for the diagnosis of Parkinson's disease. Neurodegen. Dis. 2010, 7:284-290.
155. Ren P.-H., Lauckner J.E., Kachirskaia I., Heuser J.E., Melki R., Kopito R.R. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 2009, 11:219-225.
156. Ridley R.M., Baker H.F., Windle C.P., Cummings R.M. Very long term studies of the seeding of β-amyloidosis in primates. J. Neural Transm. 2005, 113:1243-1251.
157. Ross G.W., Petrovitch H., Abbott R.D., Tanner C.M., Popper J., Masaki K., Launer L., White L.R. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann. Neurol. 2008, 63:167-173.
158. Rustom A., Saffrich R., Markovic I., Walther P., Gerdes H.-H. Nanotubular highways for intercellular organelle transport. Science 2004, 303:1007-1010.
159. Sacks O. The origin of " Awakenings" . Br. Med. J. (Clin. Res. Ed.) 1983, 287:1968-1969.
160. Saman S., Kim W., Raya M., Visnick Y., Miro S., Saman S., Jackson B., McKee A.C., Lee N.C., Hall G.F. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid (CSF) in early Alzheimer's Disease. J. Biol. Chem. 2011.
161. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
162. Savica R., Rocca W.A., Ahlskog J.E. When does Parkinson disease start?. Arch. Neurol. 2010, 67:798-801.
163. Savica R., Carlin J.M., Grossardt B.R., Bower J.H., Ahlskog J.E., Maraganore D.M., Bharucha A.E., Rocca W.A. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009, 73:1752-1758.
164. Schapira A.H.V. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol. Sci. 2009, 30:41-47.
165. Schapira A.H.V., Emre M., Jenner P., Poewe W. Levodopa in the treatment of Parkinson's disease. Eur. J. Neurol. 2009, 16:982-989.
166. Schapira A.H.V., Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann. Neurol. 2006, 59:559-562.
167. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388-393.
168. Schnabel J. Amyloid: little proteins, big clues. Nature 2011, 475:S12-S14.
169. Schorey J.S., Bhatnagar S. Exosome function: from tumor immunology to pathogen biology. Traffic 2008, 9:871-881.
170. Schweers O., Schönbrunn-Hanebeck E., Marx A., Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J. Biol. Chem. 1994, 269:24290-24297.
171. Selikhova M., Williams D.R., Kempster P.A., Holton J.L., Revesz T., Lees A.J. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009, 132:2947-2957.
172. Shannon K.M., Keshavarzian A., Mutlu E., Dodiya H.B., Daian D., Jaglin J.A., Kordower J.H. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov. Disord. 2011.
173. Sharples R.A., Vella L.J., Nisbet R.M., Naylor R., Perez K., Barnham K.J., Masters C.L., Hill A.F. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J. 2008, 22:1469-1478.
174. Shulman L.M., Taback R.L., Bean J., Weiner W.J. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov. Disord. 2001, 16:507-510.
175. Simons M., Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 2009, 21:575-581.
176. Simón-Sánchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
177. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
178. Small S.A., Kent K., Pierce A., Leung C., Kang M.S., Okada H., Honig L., Vonsattel J.-P., Kim T.-W. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann. Neurol. 2005, 58:909-919.
179. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
180. Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
181. Steiner J.A., Angot E., Brundin P. A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ. 2011.
182. Stiasny-Kolster K., Doerr Y., Möller J.C., Höffken H., Behr T.M., Oertel W.H., Mayer G. Combination of " idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005, 128:126-137.
183. Su L.J., Auluck P.K., Outeiro T.F., Yeger-Lotem E., Kritzer J.A., Tardiff D.F., Strathearn K.E., Liu F., Cao S., Hamamichi S., et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis. Model Mech. 2010, 3:194-208.
184. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 2008, 29:1690-1701.
185. Sullivan C.P., Jay A.G., Stack E.C., Pakaluk M., Wadlinger E., Fine R.E., Wells J.M., Morin P.J. Retromer disruption promotes amyloidogenic APP processing. Neurobiol. Dis. 2011, 43:338-345.
186. Sung J.Y., Park S.M., Lee C.-H., Um J.W., Lee H.J., Kim J., Oh Y.J., Lee S.-T., Paik S.R., Chung K.C. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J. Biol. Chem. 2005, 280:25216-25224.
187. Sung J.Y., Kim J., Paik S.R., Park J.H., Ahn Y.S., Chung K.C. Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J. Biol. Chem. 2001, 276:27441-27448.
188. Tan E.K., Chai A., Teo Y.Y., Zhao Y., Tan C., Shen H., Chandran V.R., Teoh M.L., Yih Y., Pavanni R., et al. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology 2004, 62:128-131.
189. Thal D.R., Capetillo-Zarate E., Del Tredici K., Braak H. The development of amyloid beta protein deposits in the aged brain. Sci. Aging Knowledge Environ. 2006 2006, re1.
190. Trexler A.J., Rhoades E. Single molecule characterization of α-synuclein in aggregation-prone states. Biophys. J. 2010, 99:3048-3055.
191. Uversky V.N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 2003, 21:211-234.
192. van de Warrenburg B.P., Lammens M., Lücking C.B., Denèfle P., Wesseling P., Booij J., Praamstra P., Quinn N., Brice A., Horstink M.W. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001, 56:555-557.
193. Vella L.J., Sharples R.A., Lawson V.A., Masters C.L., Cappai R., Hill A.F. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J. Pathol. 2007, 211:582-590.
194. Vilariño-Güell C., Wider C., Ross O.A., Dachsel J.C., Kachergus J.M., Lincoln S.J., Soto-Ortolaza A.I., Cobb S.A., Wilhoite G.J., Bacon J.A., et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 2011, 89:162-167.
195. Volpicelli-Daley L.A., Luk K.C., Patel T.P., Tanik S.A., Riddle D.M., Stieber A., Meaney D.F., Trojanowski J.Q., Lee V.M.-Y. Exogenous α-synuclein fibrils induce lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72:57-71.
196. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
197. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., Lansbury P.T. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001, 40:7812-7819.
198. Vonsattel J.P.G., Keller C., Cortes Ramirez E.P. Huntington's disease-neuropathology. Handb. Clin. Neurol. 2011, 100:83-100.
199. Walker R.W., Hand A., Jones C., Wood B.H., Gray W.K. The prevalence of Parkinson's disease in a rural area of North-East England. Parkinsonism Relat. Disord. 2010, 16:572-575.
200. Waxman E.A., Giasson B.I. A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J. Neurochem. 2010, 113:374-388.
201. Weisman D., McKeith I. Dementia with Lewy bodies. Semin. Neurol. 2007, 27:42-47.
202. Williams-Gray C.H., Evans J.R., Goris A., Foltynie T., Ban M., Robbins T.W., Brayne C., Kolachana B.S., Weinberger D.R., Sawcer S.J., et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009, 132:2958-2969.
203. Winslow A.R., Chen C.-W., Corrochano S., Acevedo-Arozena A., Gordon D.E., Peden A.A., Lichtenberg M., Menzies F.M., Ravikumar B., Imarisio S., et al. α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 2010, 190:1023-1037.
204. Wolfe M.S. Tau mutations in neurodegenerative diseases. J. Biol. Chem. 2009, 284:6021-6025.
205. Xilouri M., Stefanis L. Autophagic pathways in Parkinson disease and related disorders. Expert Rev. Mol. Med. 2011, 13:e8.
206. Yang W., Dunlap J.R., Andrews R.B., Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Gen. 2002, 11:2905-2917.
207. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
208. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.-S., et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19:533-542.
209. Zhang Y.-W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer's disease. Mol. Brain 2011, 4:3.
210. Zimprich A., Benet-Pagès A., Struhal W., Graf E., Eck S.H., Offman M.N., Haubenberger D., Spielberger S., Schulte E.C., Lichtner P., et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 2011, 89:168-175.